Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7796]

ESMO 2014: Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

ESMO 2014: Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

ESMO 2014: Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

ESMO 2014: Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

ESMO 2014: Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemo

ESMO 2014: Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemo

ESMO 2014: Adding cediranib to chemo improves PFS for metastatic cervical cancer

ESMO 2014: Adding cediranib to chemo improves PFS for metastatic cervical cancer

ESMO 2014: Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

ESMO 2014: Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive...

ESMO 2014: Docetaxel or pemetrexed in addition to cisplatin achieve comparable outcomes in non-squamous lung cancer

ESMO 2014: Docetaxel or pemetrexed in addition to cisplatin achieve comparable outcomes in non-squamous lung cancer

ESMO 2014: Thymidylate synthase as a predictive and prospective biomarker in lung cancer

ESMO 2014: Thymidylate synthase as a predictive and prospective biomarker in lung cancer

ESMO 2014: Scan may identify lung cancer patients who will benefit from folate-targeted drug

ESMO 2014: Scan may identify lung cancer patients who will benefit from folate-targeted drug

ESMO 2014: Second-line afatinib significantly improves PFS in metastatic head and neck cancer

ESMO 2014: Second-line afatinib significantly improves PFS in metastatic head and neck cancer

ESMO 2014: Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

ESMO 2014: Anamorelin improves appetite and body mass in non-small cell lung cancer with cancer anorexia-cachexia

More from ecancer